TfR mAb-Cross-Linked Rituximab/MTX-PEG-PLL-PLGA Drug-Loaded Nanoparticles Enhance Anticancer Action in B Lymphocytes
UVA sensitivity and stability of Rituximab- (a), MTX- (b), or TfR mAb- (c) loaded nanoparticles. (d) The drug loading content (DLC) and drug loading efficiency (DLE) of Rituximab and MTX and the modification rate of TfR mAb in TfR mAb/Rituximab/MTX-PEG-PLL-PLGA nanoparticles.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.